trial

Peripheral Immune System in Individuals With Schizophrenia

NCTId NCT05109065
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase — · Completed
Enrollment 63 (actual)
Sponsored by Stanford University
Primary completion 2024-05-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
63 (actual)
Study type
Observational
Allocation
—
Model
—
Masking
—
Start
2021-03-01
Primary completion
2024-05-23
Eligibility
ALL · 18 Years · 40 Years

Interventions & indications

Drugs
SCID (Standardized Clinical Interview for DSM-V)PSS (Perceived Stress Score)Urine Toxicology ScreenVitalsBlood WorkPQ-BCOVID ScreeningPositive and Negative Syndrome Scale (PANSS)

Sponsors

Stanford UniversityLead Sponsor

Investigators

1
Agnieszka Kalinowski, MD PhDPrincipal Investigator

Sites

1 total
Stanford, United States

Facts & assertions

4 sourced
Enrollment
63
Phase
NA
Primary Completion Date
2024-05-23
Status
COMPLETED
relationships
The graph out of here
drug
SCID (Standardized Clinical Interview for DSM-V)
drug
PSS (Perceived Stress Score)
drug
Urine Toxicology Screen
drug
Vitals
drug
Blood Work
drug
PQ-B
drug
COVID Screening
drug
Positive and Negative Syndrome Scale (PANSS)
drug
lead_sponsor
Stanford University
company
indication
Schizo Affective Disorder
indication
Schizophreniform Disorders
indication
Psychotic Disorders
indication
investigator
Agnieszka Kalinowski, MD PhD
person